Stevanato Group (STVN) Could Be 19% Undervalued As Alina Pen Approvals Expand In Europe
Stevanato Group (STVN) stock is in focus after the company reported that liraglutide combination products using its Alina 30 and Alina 50 pen injectors received marketing authorizations in multiple European countries.
See our latest analysis for Stevanato Group.
The Alina approvals come as Stevanato Group’s share price shows mixed momentum, with a 30 day share price return of 8.23% and a 90 day share price return of 12.08%. However, the year to date share price return is down 3.55% and the 1 year total shareholder return is down 20.69%, signalling recent interest but weaker longer term outcomes for shareholders.
If this news has you thinking more broadly about drug delivery and injectable therapies, it can be useful to see what else is on the market and review 41 healthcare AI stocks.
For Stevanato Group, the question now is whether the recent share price rebound reflects investors reassessing the underlying drug delivery business, or a short term swing in sentiment that the valuation section can help you frame.
Most Popular Narrative: 18.6% Undervalued
The most followed narrative on Stevanato Group frames a fair value of $24.39 against a last close of $19.85, which implies meaningful upside if the underlying assumptions play out as expected.
The growing prevalence of biologics and novel drug classes (including GLP-1s, mAbs, and biosimilars) is driving robust, increasing demand for Stevanato's high-value containment and delivery solutions, evidenced by high growth rates in these product lines and strong order pipelines from major pharma clients, which supports ongoing revenue expansion.
Want to understand why this narrative still assigns a premium earnings multiple and higher margin profile to Stevanato Group? The entire valuation hangs on how quickly higher value drug delivery solutions reshape its revenue mix and long term profitability.
Result: Fair Value of $24.39 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still real pressure points for Stevanato Group, including rising capital and operating costs, as well as heavy reliance on a small group of large biopharma customers.
Find out about the key risks to this Stevanato Group narrative.
Next Steps
If the mix of risks and rewards around Stevanato Group leaves you unsure, do not wait for the crowd to settle the debate. Review the 3 key rewards
Looking for more Stevanato Group sized investment ideas?
If Stevanato Group has sharpened your focus on quality opportunities, do not stop here. Use Simply Wall Street's screener to spot other stocks that could suit your approach.
- Target potential mispricings by reviewing companies that appear out of favor on fundamentals through the 55 high quality undervalued stocks.
- Strengthen your income stream by assessing resilient payers using the 9 dividend fortresses.
- Protect your capital by searching for companies with robust financial positions via the 81 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com